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INTRODUCTION 
Acquired immunodeficiency syndrome (AIDS) is characterized 
by an acquired, profound, irreversible immunosuppression that 
predisposes the patient to multiple opportunistic infections, malignant 
neoplasms, and a progressive dysfunction of multiple organ systems. 
The heart and great vessels are not the sites most frequently affected by 
opportunistic infections and neoplastic processes in patients with 
acquired immune deficiency syndrome (AIDS). However, 
cardiovascular complications occur in a significant number of such 
patients and are the immediate cause of death in some. 
The prevalence of cardiac involvement in AIDS patients has been 
reported to range between 28% and 73%1. Recent advances in the 
knowledge about human immunodeficiency virus (HIV) replication  
and the treatment of HIV infection have improved survival in HIV 
patients2-4. Because of the longer survival in HIV patients, the more 
manifestations of late-stage HIV infection will be seen, including HIV 
related cardiac diseases. As patients with HIV infection are living 
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longer, they are at risk of developing chronic diseases, including 
coronary atherosclerosis too. The spectrum of cardiovascular 
complications of AIDS that may be depicted at imaging includes 
a) Dilated cardiomyopathy 
b) Pericardial effusion 
c) Human immunodeficiency virus–associated pulmonary 
hypertension 
d) Endocarditis 
e) Thrombosis 
f) Embolism 
g) Vasculitis 
h) Aneurysm 
i) Coronary artery disease 
j) Cardiac involvement in AIDS-related tumors. 
In this article, we review the pathophysiologic and imaging 
manifestations of HIV and AIDS  related cardiovascular complications. 
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OBJECTIVE 
             To identify the incidence of cardiovascular diseases in various 
stages of AIDS by clinical profile, electrocardiogram and 
echocardiography.  
DESIGN 
Prospective, clinical, and echocardiographic study. 
SELECTION OF PATIENTS 
INCLUSION CRITERIA: 
150 consecutive HIV-infected patients attending the Institute of 
Internal Medicine both as inpatients and outpatients who were positive 
for  HIV antibodies were included in this prospective study irrespective 
of their  duration of their illness and ART status. 
EXCLUSION CRITERIA: 
Patients with evidence of heart disease previous to the diagnosis 
of  their HIV infection were specifically excluded. 
STUDY DURATION: JAN 2009 TO JUNE 2010 
SAMPLE SIZE:              150 patients 
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MATERIALS AND METHODS 
150 consecutive HIV infected patients attending the Institute  of 
Internal Medicine both as inpatients and outpatients who were positive  
for HIV antibodies were selected. 
All the patients were given a thorough clinical examination that 
included a patient history, a physical examination. Routine lab 
investigations like RFT, LFT, CHG, fasting blood sugar and CD4 count 
were taken.  ECG and two-dimensional echocardiography were taken 
and cardiac findings were analyzed statistically.  
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REVIEW OF LITERATURE 
Cardiac involvement in AIDS was first reported in 1983 by 
Autranet al5. They described a 24 years old Haitian woman with 
multiple complications of AIDS who, at postmortem, had Kaposi's 
sarcoma (KS) involving the entire anterior cardiac wall without 
pericardial effusion. Since the time of that report, the understanding and 
the documentation of AIDS related complications have evolved 
considerably and reports of lesions related to the heart have increased. 
               It is now apparent that HIV, secondary opportunistic 
infections, and the medical treatment itself of HIV disease can all affect 
the heart6-8. The spectrum of abnormalities ranges from clinically silent 
lesions detected on postmortem examination to clinically potentially 
fatal diseases, such as pericardial tamponade. 
PERICARDIAL EFFUSION 
 The spectrum of pericardial disease in HIV infected patients is 
wide. It ranges from asymptomatic effusions detected on 
echocardiography to potentially fatal tamponade and constrictive 
pericardial disease 9-12. 
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ETIOLOGY 
Acute and chronic pericarditis can also occur. Pericardial disease 
in HIV-infected patients may have infectious, noninfectious, or 
neoplastic etiologies. Infectious causes of pericardial disease in 
HIV/AIDS include viruses, bacteria, and fungi. Cytomegalovirus (CMV) 
is a frequent pathogen in patients with AIDS and has been reported to 
cause cardiac tamponade in a patient with cryptococcal meningitis13. 
Herpes simplex virus is also reported as a cause of pericarditis in AIDS 
patients14-15. It remains unclear whether HIV itself can independently 
cause pericarditis16. Bacterial pericarditis can be caused by 
Staphylococcus aureus17-18 and Klebsiella pneumoniae19, as well  
as Nocardiaasteroides, Mycobacterium tuberculosis20-21, and 
Mycobacterium avium complex  in HIV-infected patients with 
Disseminated infections. Fungal pericarditis secondary to Cryptococcus 
neoformans22-23 has also been reported. Cardiac lymphoma in HIV 
patients has been described in many reports24-25. It can be primary or 
secondary and can involve the pericardium. Kaposi Sarcoma has also 
been described and can affect the pericardium as well as the epicardium 
and can rarely cause tamponade. Nonetheless, many pericardial 
effusions appear to be idiopathic26. 
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CLINICAL FEATURES 
The clinical picture of pericardial disease can be silent or may 
present with chest discomfort, dyspnoea and fever. Physical examination 
may reveal tachycardia, tachypnoea, and friction rub. Cardiac 
tamponade usually manifests with tachypnoea, hypotension with pulsus 
paradoxus, elevated jugular venous pressure and distant heart sounds. 
"Low-pressure tamponade" is a phenomenon that is sometimes observed 
in AIDS patients who are severely dehydrated or cachectic; the severe 
volume depletion may cause reduced right ventricular filling pressure, 
and a minimal pericardial effusion may cause a hemodynamically 
significant tamponade. In this setting, elevation of jugular venous 
pressure or pulsus paradoxus may be absent27. The cardiac dysfunction 
may be easily obscured or unrecognized because the clinical picture of 
AIDS may be so overwhelmingly dominated by the impact of 
opportunistic infections. 
DIAGNOSIS 
The patient's chest radiograph may or may not show an enlarged 
cardiac silhouette with classic "water-bottle" appearance depending on 
the size of effusion. Electrocardiography (ECG) may demonstrate ST-T 
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wave changes indicative of pericarditis. As pericardial effusion 
increases, low QRS voltage and electrical alternans may appear. 
Echocardiography is an excellent diagnostic tool for detecting and 
monitoring pericardial effusion and tamponade28-30. 
TREATMENT 
            When clinically significant pericardial effusion is encountered in 
an HIV infected patient, the differential diagnosis should first exclude 
the non HIV related causes, such as renal failure, trauma, radiation 
effect, drug toxicity, connective tissue diseases, and hypothyroidism. 
Small asymptomatic effusions can be observed clinically and with serial 
echocardiograms. Nonsteroidal anti-inflammatory agents (NSAIDs) may 
provide some relief. Corticosteroid therapy should generally be avoided 
because of the likelihood of concurrent infection, which may be 
exacerbated by steroid therapy. Diagnostic pericardiocentesis or biopsy 
may be indicated for microbiologic and cytologic studies when an 
infectious etiology is highly suspected or when presumed infectious 
pericarditis fails to respond to empiric antibiotics. A diligent attempt 
must be made to establish an etiologic agent. This is critical because 
some of these pericardial infections (e.g., tuberculosis) are amenable to 
specific therapy, even in immunocompromised individuals. 
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Cardiac tamponade requires an urgent intervention with 
pericardiocentesis. Removal of a small amount of fluid often produces 
immediate hemodynamic benefit, but complete drainage with a catheter 
is preferable. Draining pericardiotomy or pericardiectomy may be 
appropriate for recurring effusion especially in neoplastic disease and 
chronic pericarditis. Additional therapy is determined by the extent of 
the response to initial management. 
 
 
 
 
 
 
Pericardial fluid in a 32 years old woman with AIDS and a history 
of recurrent pneumonia. Unenhanced axial computed tomographic (CT) 
scan demonstrates a medium-sized pericardial effusion (arrows), as well 
as bilateral pleural fluid collections and slight dilatation of the heart. 
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MYOCARDIAL DISEASE 
 Four forms of myocardial disease have been described in patients 
with HIV. The first is myocarditis, which may result from invasive 
opportunistic infections or lymphocytic infiltration. Non-inflammatory 
myocardial necrosis has also been described. The third form is dilated 
cardiomyopathy, and the fourth form is infiltrative myocardial disease 
caused by neoplasia such as Kaposi Sarcoma or high-grade HIV-related 
lymphoma. 
DILATED CARDIOMYOPATHY 
Dilated cardiomyopathy in the setting of HIV/AIDS reflects 
severe cardiac dysfunction. Biventricular or four-chamber dilation is the 
characteristic finding. It may be either primary31, 32 or secondary as a 
result of chronic active myocarditis, cardiotoxins, hypersensitivity 
reactions33 , and certain dietary deficiencies such as thiamine (vitamin 
B1)33,34  and selenium26.Myocardial damage related to hypersensitivity 
reaction and cardiac specific autoimmunity leading to myocarditis, 
cardiomyopathy, or both has been suggested in some published 
studies33-41. Alteration of T-helper cell function, as seen in patients with 
AIDS, may result in uncontrolled hypergammaglobinemia and high 
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concentration of serum immune complexes that have the potential for 
causing local and systemic inflammatory lesions in the major organs of 
body including the cardiac muscle itself33. Other studies  postulated that 
the HIV gene alters the surface of the cardiac muscle fiber inducing cell-
surface immunogenic proteins and leads to the formation of circulating 
cardiac auto antibodies, that can trigger a progressively destructive 
autoimmune reaction. Such heart specific auto antibodies have been 
demonstrated in some HIV-positive patients with cardiomyopathy34-41. 
Whether such immunologic changes can be attributed to only HIV 
infection remains unclear, and further research may still be needed in 
this area. 
Nutritional deficiencies and severe wasting syndrome are 
common problems in terminally-ill patients with AIDS31, 42. Vitamin 
deficiency, particularly vitamin B1, may occur in such situations and 
may play a role, although secondary, in AIDS-associated dilated 
cardiomyopathy26,33. Selenium deficiency and its association with 
cardiomyopathy in malnourished pediatric AIDS patients have also been 
described; selenium supplementation in this subgroup of AIDS patients 
has been shown to improve cardiac dysfunction42-44. It is still believed, 
however, that such nutritional deficiencies may have a secondary role in 
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the pathogenesis of cardiomyopathy, and additional studies may be 
required to determine the effect of various dietary supplements on the 
reversibility of cardiac dysfunction in these patients. 
CLINICAL FEATURES 
Clinical manifestations of myocardial lesions depend on the 
severity of the inflammatory process and the location of the lesion. 
Subclinical conditions are not uncommon. When symptomatic, the 
associated symptoms include chest pain, dyspnea, fatigue and peripheral 
edema. Palpitations, dizziness and syncope may indicate dysrhythmia. 
Physical examination may reveal signs of biventricular failure with 
valvular dysfunction. 
DIAGNOSIS 
Chest radiography shows cardiomegaly and pulmonary vascular 
redistribution. ECG may reveal various types of dysrhythmias and even 
a pseudoinfarct pattern. Echocardiography is helpful in diagnosing 
cardiomyopathies and to a lesser extent, neoplastic infiltrations, which 
are more likely to be detected on CT or MR. Isolation and identification 
of specific etiologic agents are critically important especially in life-
threatening conditions. The necessity of performing myocardial biopsy 
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remains controversial, and the risk associated with this procedure may 
be significant. It may be diagnostically helpful in rare situations, 
particularly in the setting of isolated cardiac tumors and in patients with 
extensive cardiac damage and poor prognosis without a known 
identifiable cause. However, it may be of limited sensitivity, especially 
in patchy lesions and only rarely useful in the management of the 
patient. It is a procedure that has considerable risks, which should 
always be weighed against the expected benefit.  
TREATMENT 
HIV-related cardiomyopathy and associated congestive heart 
failure (CHF) may respond to standard management, including inotropic 
agents, diuretics and vasodilators. Antidysrhythmics should be used 
where indicated. The spectrum of dysrhythmia in patients with 
myocarditis may be wide. It includes various atrial and ventricular 
rhythm disturbances as well as various degrees of heart block. The 
antidysrhythmic agents to be used depend on the type of dysrhythmia, 
its hemodynamic consequences, and the associated adverse effects that 
may accompany the use of such agents, for example, negative inotropic 
effect45. 
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Anticoagulants may also be used in certain conditions, such as 
atrial fibrillation or when the left ventricular systolic function is 
markedly reduced. However, the benefit of anticoagulation should 
always be balanced against the risk of having a bleeding complication 
especially in AIDS patients; not only because myocarditis may be 
associated with pericardial disease, which may lead to intra pericardial 
hemorrhage, but also because AIDS patients are at higher risk of having 
vasculopathy with aneurysmal formation that may lead to intra cerebral 
bleeding from mycotic aneurysms9. 
 
Dilated cardiomyopathy in a 38 years old man with AIDS.  
Radiograph shows an enlarged cardiac silhouette with left ventricular 
enlargement 
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Apical four-chamber echocardiographic view shows marked 
enlargement of all four chambers, as well as spontaneous echo contrast 
(“smoke”) in the left-sided chambers because of a very low ejection 
fraction and sluggish flow. 
 
Contrast-enhanced axial CT scan demonstrates significantly 
enlarged right and left ventricles and a dilated inferior vena cava 
(arrowhead) and coronary sinus (arrow), as well as pericardial fluid, 
right-sided pleural effusion, and parenchymal consolidation in the lower 
lobe of the right lung. 
16 
 
MYOCARDITIS 
Myocarditis in HIV patients may play a role in the development 
of ventricular dysfunction.The autopsy incidence of myocarditis was 
approximately one third of all AIDS patients. A specific cause was 
found in less than 20% of these patients. Common pathogens in AIDS 
myocarditis include Toxoplasma gondii,    Mycobacterium tuberculosis 
and Cryptococcus neoformans. Other infectious organisms have been 
reported to include Myocobacterium avium-intracellulare complex, 
Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum, 
Coccidioides immitis, cytomegalovirus, and herpes Simplex 1 and 226. 
Recent data suggested that HIV alone can cause myocarditis. Either HIV 
or its proteins(p17, p24, and gp120/160) have been found in the heart 
specimens of patients with AIDS with or without cardiac diseases by 
culture, in situ deoxyribonucleic acid hybridization, and by Southernblot 
tests46-48. 
Superantigen plays an important role in the pathogenesis of many 
diseases by forming a trimolecular complex with major 
histocompatibility complex class II molecule on the antigen-presenting 
cells and the V -specific region on the T-lymphocyte receptor49. The 
binding results in a massive stimulation of the T lymphocyte. After the 
17 
 
binding of HIV regulatory protein (Nef) with major histocompatibility 
complex class II on antigen-presenting cells, the T lymphocytes become 
activated. The activation of T lymphocyte stimulates the proliferation 
and release of cytokines such as interferon  and interleukin 2. 
Therefore, the viral load in the heart will increase from creating a 
cellular reservoir for HIV. T lymphocyte depletion may be caused by 
apoptosis, anergy or both. Proliferation of the B cell may result in 
hypergammaglobulinemia. Autoimmune response may occur as a result 
of  B cell differentiation into immunoglobulin-secreting cells and 
activation of the T lymphocyte. 
Lymphocytic myocarditis was found in 37 of 71 patients who 
died of AIDS50. There were 3 types of histological features: lymphocytic 
infiltrate with necrosis of the myocardial fibers,lymphocytic infiltrate 
without necrosis of the myocardial fibers51, and focal and mild 
myocarditis with a mononuclear infiltrate50. 
PULMONARY HYPERTENSION 
It is more common in male and young patients (mean age, 32 
years). The common risk factors are intravenous drug use, homosexual 
contacts and hemophilia. The major symptom of this conditionis 
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dyspnea52. There was no correlation between both a history of 
opportunistic infections or CD4 cell count and the development of 
pulmonary hypertension. The mean pulmonary artery systolic pressure 
was 68 mm Hg. The major causes of death were right sided heart failure 
and respiratory failure. 
The exact mechanism by which pulmonary arterial hypertension 
develops is not clear, although various causal factors have been 
proposed, including genetic predisposition, peri-vascular inflammation, 
increased expression of vascular endothelial growth factor A (a potent 
inducer of the growth of endothelial cells, which increases vascular 
permeability) in T cells, increased expression of intrapulmonary 
platelet-derived growth factor, and HIV-induced release of active 
endothelial cellular mediators52. Glycoprotein 120, an HIV-1 envelope 
glycoprotein, has been found to stimulate the production of endothelin 1 
and tissue necrosis factor α and too chronically increase the expression 
of endothelin 1, a pulmonary vasoconstrictor52.  
In most of cases, pulmonary arterial hypertension is due solely to 
HIV infection. Pulmonary arterial hypertension also has been attributed 
to recurrent pulmonary infection with secondary pulmonary 
inflammation and fibrosis, to intravenous drug abuse, and to cirrhosis.  
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Findings at histopathologic analysis of lung tissue from patients 
with the condition are similar to those of primary pulmonary 
hypertension. The most common finding is plexogenic pulmonary 
arteriopathy52,53. Less common pathologic findings include medial 
hypertrophy and intimal fibrosis without plexiform lesions, pulmonary 
veno-occlusive disease and thrombotic pulmonary arteriopathy52. 
The imaging findings in these patients also are similar to those 
observed in primary pulmonary arterial hypertension. They include 
enlargement of the pulmonary artery trunk, prominence of the central 
pulmonary arteries, tapering of peripheral vessels, and an enlarged 
cardiac silhouette secondary to right ventricular and right atrial 
dilatation (72% of patients). Abnormalities in cardiac morphologic 
features may be visualized with contrast-enhanced CT. These include 
right atrial and ventricular dilatation, often with reversal of the curvature 
of the interatrial and interventricular septa followed by tricuspid 
regurgitation and paradoxical septal motion52. Other echocardiographic 
findings are right ventricular wall hypertrophy, septal impingement on 
the left ventricle and pulmonary valve insufficiency54. 
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Apical four-chamber view of the heart depicts marked 
enlargement of the right-sided chambers, with a right ventricular 
diameter almost twice the diameter of the left ventricle 
 
 
Contrast-enhanced CT scan depicts the abnormal prominence of 
the main trunk of the pulmonary artery (35 mm) (straight arrow). 
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ENDOCARDITIS 
Marantic endocarditis or nonbacterial thrombotic endocarditis is 
characterized by friable, fibrinous clumps of platelets and red blood 
cells adherent to the cardiac valves without an inflammatory reaction. It 
is estimated that this condition occurs in 3% to5% of AIDS patients55. 
Marantic endocarditis is known to be associated with malignant 
neoplasms, hypercoagulable states, and chronic wasting disease56-58. 
Mitral and aortic valves are commonly involved in HIV-negative 
patients57, but the tricuspid valve is usually involved in AIDS patients50. 
Systemic embolism can occur in upto 42% of patients, but most of these 
events are clinically silent. Embolization can involve the brain, lung, 
spleen, kidney and coronary arteries59. Systemic embolization from 
marantic endocarditis is a rare cause of death in AIDS patients. 
Infective endocarditis in patients with AIDS usually occurs in 
parenteral drug users. Human immunodeficiency virus infection may 
increase the risk of infective endocarditis among intravenous drug users. 
The major causes of infective endocarditis in HIV patients are 
Staphylococcus aureus and Streptococcus viridans. Other unusual 
organisms described as case reports were Salmonella, Aspergillus 
fumigatus and Pseudallescheriaboydii. The tricuspid valve is the most 
22 
 
commonly affected valve. The affected patients usually present with 
fever, sweats, weight loss and coexisting pneumonia and / or meningitis. 
The presentation and survival of infective endocarditis in patients with 
and without HIV infection are generally not different; however, in the 
late stage of HIV-infected patients, significant increased mortality from 
infective endocarditis has been reported compared with asymptomatic 
HIV patients60. 
 
Right parasternal long-axis four-chamber echocardiographic view 
shows marked right atrial enlargement and a large area of echogenicity 
adjacent to the tricuspid valve. 
23 
 
 
Axial chest CT scans obtained with lung window settings 
demonstrate cavitary and noncavitary nodules (arrows in a) in both 
lungs. 
VASCULITIS 
A range of inflammatory vascular diseases, both infective and 
noninfective, may occur in the setting of HIV. These include 
polyarteritis nodosa, Henoch-Schönlein purpura and drug-induced 
hypersensitivity vasculitis61. Features similar to those in Kawasaki 
syndrome, coronary arteritis and Takayasu arteritis also have been 
described62.  
Large-vessel disease may be aneurysmal or occlusive. Aneurysms 
may be single or multiple and may affect vessels such as the aorta or the 
common carotid, common iliac, femoral, or popliteal arteries63. 
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Occlusive disease has been reported in Africa in young HIV-positive 
patients and is less common than aneurysmal dilatation63,64. In both 
processes, the main histopathologic features are found in the adventitia, 
with leukocytoclastic vasculitis of the vasa vasorum and periadventitial 
vessels, chronic inflammation and fibrosis. Accelerated atherosclerosis 
also was found responsible for aortic aneurysm in a young man who had 
undergone several  years of HAART for AIDS 65. 
 
Contrast-enhanced CT scan of the abdomen shows the dilated 
aorta with a mural thrombus (arrow). 
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THROMBOSIS AND EMBOLISM: 
HIV-infected patients tend to develop coagulation abnormalities 
due to increased levels of fibrinogen, d-dimer, plasminogen activator 
inhibitor-1, and tissue-type plasminogen activator antigen. A deficiency 
of protein S also has been identified. These hematologic abnormalities 
are associated with both arterial and venous thrombosis, especially in 
patients who are undergoing therapy with protease inhibitors 66,67. In a 
series of HIV-positive patients with venous or arterial thrombosis, deep 
vein involvement, most commonly in a lower extremity, and secondary 
pulmonary emboli accounted for 66% of all thrombotic events. 
Persistent antiphospholipid antibodies were the most common abnormal 
serologic finding68. An association between cigarette smoking and 
spontaneous thrombosis in HIV patients has been mentioned 67 and was 
reported to affect 77% of the patients in one series68. 
 
Contrast-enhanced chest CT scans show bilateral pulmonary 
embolisms (arrows). 
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CORONARY ARTERY DISEASE 
Antiretroviral medications have dramatically reduced the overall 
death rate among patients with the human immunodeficiency virus 
(HIV), but those same patients may now face an increased risk for 
cardiovascular disease (CVD) 69. 
Many patients infected with HIV have cholesterol abnormalities 
which may be side effects from the antiretroviral medications, effects of 
the virus, or both. Also common in this population are traditional risk 
factors for cardiovascular disease such as insulin resistance, diabetes, 
the tendency to carry excess weight in the mid-section, kidney 
abnormalities and more, which might be influenced by the HIV drug 
regimen or the virus itself. In addition, there is a high prevalence of 
smoking in HIV-infected individuals.  
Scientists and healthcare providers convened in June 2007 for the 
State of the Science Conference: Initiative to Decrease Cardiovascular 
Risk and Increase Quality of Care for Patients Living with HIV/AIDS, a 
joint effort of the American Heart Association and the American 
Academy of HIV Medicine. 
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Among the group’s key findings: 
♣  The risk for heart attack is 70 percent to 80 percent higher among 
people  with HIV compared to those who do not have HIV, 
although the absolute risk still remains low for younger patients. 
♣  Having HIV is associated with increases in two important risk 
factors for heart disease:  
• low levels of HDL cholesterol (high-density lipoproteins or 
“good cholesterol) and  
• elevated levels of triglycerides. 
♣ Large studies suggest that the cardiovascular disease increase 
among HIV- Infected patients is associated with specific 
metabolic abnormalities linked to antiretroviral therapy, including 
diabetes, as well as traditional risk factors such as  smoking. 
♣ While it’s easy to assume that long-term ART use could further 
increase  cardiovascular risk for these patients, the research 
suggests that uninterrupted ART treatment may reduce 
cardiovascular risk. 
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♣ It is important to stratify CVD risk in HIV-infected patients. 
Clinicians can use existing general risk stratification algorithms, 
such as the Framingham Risk Score, to measure HIV patients’ 
risk for heart disease, as this algorithm performs reasonably well 
in the HIV population although it does not incorporate specific 
HIV factors. Development of well-validated HIV specific risk-
prediction equations is an important future research priority. 
♣ Whether the elevated risk for heart disease is more attributed to 
the disease, ART or an interaction between the two is not yet 
clear69. 
HIV AND DIABETES 
Human immunodeficiency virus (HIV) patients with heart disease 
or diabetes have a higher risk for subsequent coronary events than HIV 
patients without heart disease or diabetes, according to a report in 
Circulation: Journal of the American Heart Association69. 
Researchers investigated the risk of a new episode of coronary 
heart disease from a database of more than 33,000 HIV patients in 
Europe, Australia and the United States according to their histories of 
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coronary heart disease and whether they had diabetes or not. They 
found: 
• Six-hundred and ninety-eight HIV patients experienced a 
coronary heart disease event, such as heart attack, the need for 
a coronary procedure or death, during the data collection from 
1999 to 2007.  
•  Patients who had previously had a coronary heart disease 
event were 7.5 times  more  likely  to have a new  event  
compared  to  those  who  had  not previously had an event.  
• Patients with diabetes were 2.4 times more likely to experience 
a coronary heart disease event than those without diabetes. 
 
An increasing number of HIV patients are being diagnosed with 
diabetes, which may be a result of high levels of conventional risk 
factors (such as older age, physical inactivity and obesity). But diabetes 
may also occur as a side effect of some of the drugs used to treat HIV.  
There is a need for targeted interventions, such as regular physical 
exercise, smoking cessation and use of cholesterol-lowering drugs, to 
reduce the risk of coronary heart disease in patients with diabetes and 
also in those with a history of a coronary heart disease in patients  
with HIV. 
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HIV AND DYSLIPIDEMIA 
HIV has been associated with dyslipidemia independent of 
antiretroviral therapy70.Grunfeld et al found that HIV infection was 
associated with elevated triglyceride levels that worsened with 
progression of HIV-related disease71.  
Antiretroviral therapy can also contribute to dyslipidemia. 
Dyslipidemia has been described as being more common and more 
severe in HIV patients receiving antiretroviral therapy than in patients 
not on therapy72-74. The severity of the dyslipidemia and the typical 
pattern of the lipid profile differ among and within the classes of 
antiretroviral agents. Also, dyslipidemia does not develop in everyone 
who takes these medications, suggesting that host factors play a major 
role in its development. 
Non-nucleoside reverse transcriptase inhibitors have been 
associated with elevated levels of high-density lipoprotein cholesterol 
(HDL-C) and total cholesterol75. Nucleoside reverse transcriptase 
inhibitors, on the other hand, are heterogeneous in their lipid effects, 
which may depend somewhat on interactions with other antiretroviral 
drugs in the regimen76,77. For example, stavudine is often associated 
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with elevated total cholesterol, low-density lipoprotein cholesterol 
(LDL-C) and triglyceride levels. Protease inhibitors are generally 
associated with elevated levels of total cholesterol and triglycerides. 
TREATMENT OF CORONARY RISK FACTORS IN HIV 
PATIENTS 
Several measures can help prevent cardiovascular disease, 
including both lifestyle changes and medical interventions. The National 
Cholesterol Education Program recommends a Therapeutic Lifestyle 
Changes (TLC) program that includes a low-fat diet, weight control, and 
increased physical activity. 
Monitoring 
All adults should receive periodic blood lipid profiles; a profile 
done after fasting for 8-12 hours is most (In people with a triglyceride 
level above 400 mg/dL, LDL should be measured separately rather than 
derived from an equation.) People starting anti-HIV therapy should have 
a fasting lipid profile done before treatment begins and every 6-12 
months during treatment (or every 1-2 months if baseline lipid levels are 
high or a person has other risk factors). Blood glucose also should be 
measured before antiretroviral therapy begins and periodically during 
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treatment. A family medical history and questionnaire about lifestyle 
factors is important in helping assess cardiovascular risk. 
Smoking cessation 
 Quitting smoking, or even cutting down, is one of the most 
important steps people can take to reduce their cardiovascular risk. In 
some cases nicotine patches or gum, or the antidepressant bupropion 
may be used to aid smoking cessation. 
Heart-healthy diet 
 A healthy diet includes reduced amounts of fats and cholesterol. 
The NCEP recommends that 30% or less of total daily calories should 
come from fat. No more than 10% should come from saturated fat (7% 
or less if a person is at increased risk for heart disease). The diet should 
include no more than 300 mg cholesterol daily (200 mg for a person at 
increased risk for heart disease). Sodium consumption should be no 
more than 2,400 mg per day. The NCEP also recommends reduced 
alcohol consumption.  
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Healthy weight 
 Weight loss can help lower LDL and triglyceride levels and 
increase HDL levels. However, if wasting is a problem it may be 
difficult to obtain adequate calories on a very low fat diet. It is important 
to consider the relative benefits and risks for each individual. If more 
calories are needed, it is better to obtain them in the form of unsaturated 
rather than saturated fat. 
Increased physical activity 
Exercise can lower LDL and VLDL levels and raise HDL levels; 
it also can help lower blood pressure. Aerobic exercise works out the 
heart and lungs. Even moderate exercise -- such as walking 30 minutes 
per day several times a week  can improve cardiovascular health. 
Lipid-lowering drugs  
 Drugs that reduce high blood fat levels may be used if lifestyle 
modifications are not adequate. Studies in the general population have 
shown that cholesterol-lowering drugs successfully decrease total and 
LDL cholesterol levels and reduce the risk of cardiovascular disease. 
These drugs have not been thoroughly studied in people with HIV, but 
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early results suggest they are effective. However, some lipid-lowering 
drugs can interact with antiretroviral drugs and should be used with 
caution. 
• Statins are first-line therapy for high cholesterol in HIV negative 
people; they also may help reduce triglyceride levels. The Adult 
AIDS Clinical Trial Group (AACTG) Cardiovascular Disease 
Focus Group recommends starting with low doses of pravastatin 
or atorvastatin , which are least likely to interact with Protease 
Inhibitors. Lovastatin, simvastatin, and fluvastatin  are 
metabolized by the same CP450 liver enzyme system as PIs, and 
concurrent use can lead to high drug levels and intensified side 
effects; these drugs are contraindcated with PIs. Statins may cause 
muscle toxicity. 
• Fibrates are used to treat high triglycerides or 
hypercholesterolemia accompanied by high triglycerides. This 
class includes fenofibrate and gemfibrozil. According to the 
AACTG focus group, these drugs are unlikely to interact with 
antiretroviral drugs, but this has not been well studied and they 
should be used with caution. 
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• Bile sequesterants such as cholestyramine and colestipol are 
used to decrease cholesterol levels; however, in some cases these 
drugs have been associated with increased triglyceride levels, and 
their interactions with antiretroviral drugs have not been well 
studied. The AACTG focus group discourages their use in people 
receiving HAART. 
• Nicotinic acid (niacin) is also used to lower LDL cholesterol. 
Side effects include skin flushing and itching. The drug also can 
cause insulin resistance, and the AACTG focus group does not 
recommend it for people taking antiretroviral drugs that are 
themselves associated with insulin resistance. 
Diabetes management 
 People taking HAART should have their blood sugar monitored 
regularly and be alert for early signs of diabetes such as frequent 
urination and increased hunger and thirst. To manage insulin resistance 
and diabetes, AACTG focus recommend that diet modification and 
increased exercise be tried first, followed by oral anti-diabetes agents 
such as the glitazone drugs and metformin . Diabetes drugs should be 
used with caution in people taking antiretroviral drugs. 
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Blood Pressure Control 
 Diet modification and exercise should be the first steps in 
controlling hypertension. Sodium consumption can lead to high blood 
pressure, and the NCEP recommends no more than 2,400 mg per day. If 
these measures are inadequate, hypertension-reducing drugs  including 
ACE inhibitors, beta blockers, calcium channel blockers, diuretics, and 
vasodilators -- may be used. According to the AACTG focus group, no 
class of antihypertensives is completely contraindicated with HAART, 
but calcium channel blockers should be used with caution due to 
potential interactions with PIs. 
Changes in Antiretroviral Therapy 
 Switching to a protease-sparing regimen or to a PI that is less 
likely to cause metabolic abnormalities may be done in conjunction with 
or instead of lipid-lowering drugs. Drs. Falusi and Aberg recommed that 
providers initially attempt to manage hyperlipidemia without switching 
HAART regimens, especially if the person is adherent, is otherwise 
tolerating their drugs, and has good virologic control. In people with 
existing cardiovascular risk factors, however, it may be prudent to start 
with or switch to a regimen with fewer metabolic side effects. 
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CARDIAC TUMOURS 
Various malignancies are associated with AIDS both in adults and 
children. Kaposi sarcoma, non-Hodgkin lymphoma, squamous cell 
carcinoma, Hodgkin disease, and leiomyosarcoma (in children) are the 
more prevalent malignancies and are found with increasing frequency in 
patients infected with HIV79. Of these malignancies, Kaposi Sarcoma 
and non-Hodgkin lymphoma most often affect the heart.  
Kaposi Sarcoma, which is caused by human herpesvirus 8, is the 
most common cardiac tumor seen in patients with AIDS. It was 
probably the first cardiac complication of AIDS to be recognized: 
Autran et al reported a case of Kaposi sarcoma of the heart in a young 
Haitian woman with AIDS in 1983. Kaposi sarcoma is a low-grade 
malignancy that derives from mesenchymal or endothelial cells the most 
common AIDS-related neoplasm, it occurs in approximately 30% of 
patients, mostly in homosexual or bisexual males79. Cardiac 
involvement in Kaposi sarcoma in patients with AIDS usually occurs as 
part of disseminated disease. The epicardium and pericardium are the 
most frequently involved cardiac structures. Coronary wall infiltration 
and myocardial involvement also may occur. Pericardial hemorrhage 
with fatal cardiac tamponade has been described as a complication80. In 
7% of cases of cardiac tamponade in HIV-infected patients, Kaposi 
sarcoma was the cause. Isolated Kaposi sarcoma of the heart is rare.  
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Lymphoma is the second most common tumor involving the heart 
in AIDS patients. Non-Hodgkin lymphoma was added to the group of 
AIDS-defining illnesses in 1987, after a 60- to 100-fold increase in the 
rate of lymphoma was observed among patients with HIV.  Lymphoma 
is the first manifestation of AIDS in up to 4% of new cases. Primary 
cardiac malignancy associated with HIV infection is generally due to 
cardiac lymphoma81. In 80%–90% of cases, the majority of such lesions 
are high-grade B-cell tumors that consist of large cell immunoblastic or 
small non-cleaved-cell (Burkitt or Burkitt-like) lymphomas. At gross 
specimen examination, they may appear as a single mass or as multiple 
firm nodules of white tissue within the myocardium81. Any cardiac 
chamber may be affected, but the right atrium is most commonly 
involved, followed by the right ventricle, left ventricle, left atrium and 
atrial and ventricular septa. Pericardial extension is common. Secondary 
cardiac involvement in extra nodal lymphoma may manifest as a 
mediastinal mass with extension through the pericardium or as 
lymphangitic or hematogenous lesions. Chest radiographs of patients 
with cardiac lymphoma usually show cardiomegaly, pericardial 
effusion, and signs of congestive heart failure. Echocardiograms 
typically depict a hypoechoic cardiac mass with or without pericardial 
effusion. On unenhanced CT images, the tumors have soft-tissue 
attenuation equal to or less than that of myocardium.  
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Non-Hodgkin lymphoma in a young man with AIDS. Gross 
autopsy specimen shows extensive infiltration in the right ventricle 
(long white arrow), interventricular septum (black arrow), and inferior 
wall of the left ventricle (short white arrow). 
 
Contrast-enhanced CT scan in a 28 years old man with AIDS 
shows abnormal irregular thickening of the lateral wall of the left 
ventricle (arrow) and interatrial wall (arrowheads). 
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THINGS TO KNOW 
1.  Use of antiretroviral therapy (ART) has decreased overall 
mortality associated with HIV remarkably, but cardiovascular 
disease (CVD) accounts for a growing proportion of the deaths 
among HIV patients. 
2.   The relative risk of MI in HIV compared to non-HIV subjects is 
increased approximately 1.7-1.8 fold. This excess risk may 
increase further with advancing age. 
3.   HIV disease itself is associated with dyslipidemia (primarily 
increases in triglycerides and reductions in HDL).  
4.   Studies have shown the increase in CVD among HIV-infected 
patients is associated with the use of specific ARTs, metabolic 
abnormalities related to ART use such as diabetes and 
dyslipidemia and, importantly, traditional risk factors including 
smoking which is prevalent among HIV infected individuals.  
5.  There is significant variation with respect to cardio vascular 
effects in a given antiretroviral class. The contributions of these 
changes to cardiovascular risk may vary depending on the 
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presence of other risk factors. Various ART treatments have been 
shown to increase triglyceride levels, reduce glucose disposal, 
contribute to insulin resistance, result in mitochondrial 
dysfunction, lead to subcutaneous fat loss and lead to insulin 
resistance.  
6.  Despite the association of ART use with CVD, the long-term 
effects of continuous ART are unknown. Continuous suppression 
of viral load may have additional benefits beyond the known 
clinical advantages, such as reduction of inflammation or other 
undefined beneficial effects. Further research is needed to answer 
this important question. 
7.  The Framingham Risk Score is reasonably accurate in predicting 
CVD events in patients with HIV but may under-predict MI’s 
among the large group of HIV infected patients who smoke. 
Prediction might be improved upon using HIV specific equations, 
but these have not yet been validated.  
8. Progressive LV dilation in HIV infected children without 
adequate compensatory hypertrophy results in excessive LV 
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afterload, reduced LV function, and symptomatic cardiovascular 
disease. 
9.  Nonatherosclerotic heart disease, including pulmonary 
hypertension, pericardial disease and reduced cardiac contractility 
may result from both HIV infection and ART therapy.  
10.  Strategies to prevent CVD in HIV infected patients should focus 
on reduction of traditional risk factors, as well as HIV and ART 
specific risk factors. Because of virological resistance that may 
develop due to changes in ART, caution should be exercised in 
changing individual drugs and the balance of risk to benefit must 
be assessed. Use of agents for lipid lowering, insulin sensitization, 
and reduction of central adiposity as well as lifestyle strategies 
such as smoking cessation may improve individual CV risks in 
the HIV population81. 
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81.4
18.6
MALES
FEMALES
RESULTS AND OBSERVATION 
PERCENTAGE OF MALES AND FEMALES 
 
 
 
 
 
 
 No of Patients Percentage 
MALES         137      81.4% 
FEMALES         13      18.6% 
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PERCENTAGE OF VARIOUS CLINICAL STAGES OF HIV 
ANALYSED 
0
5.33
51.33
43.33
STAGE 1
STAGE 2
STAGE 3
STAGE 4
 
 No of Patients Percentage 
STAGE 1           0          0% 
STAGE 2           8          5.33%  
STAGE 3         77        51.33% 
STAGE 4         65        43.33%  
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PERCENTAGE OF CARDIAC DISEASE 
22
78
CARDIAC DISEASE
OTHERS
 
 No of Patients Percentage 
Cardiac Disease 33 22% 
Others 117 78% 
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CARDIAC DISEASES IN MALES: 
21.6
78.4
MALES
CARDIAC 
DISEASE 
21.6%
OTHERS 
 
 No of Patients Percentage 
Cardiac Disease 30 21.6% 
Others 107 78.4% 
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CARDIAC DISEASES IN FEMALES 
17.39
82.61
FEMALES
CARDIAC 
DISEASES 17.39%
OTHERS
 
 No of Patients Percentage 
Cardiac Disease 4 17.39% 
Others 9 82.61% 
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PERCENTAGE OF VARIOUS CARDIAC DISEASES IN HIV 
12.12
18.18
21.2115.15
9.09
6.06
6.06
3.03
6.06
6.06
PHT
PERICARDIAL EFFUSION
DILATED 
CARDIOMYOPATHY
CAD
Lt VENTRICULAR 
HYPERTROPHY
MVPS
DIASTOLIC DYSFUNCTION
PULMONARY 
THROMBOEMBOLISM
VALVULAR HEART 
DISEASE
MEDIASTINAL MASS
 
Cardiac Manifestations No. of Patients % 
Pericardial Effusion 6 18.18% 
Cardiomyopathy  7 21.21% 
Pulmonary Hypertension 4 12.12% 
Left Ventricular Hypertrophy 3 09.09% 
CAD 5 15.15% 
Diastolic Dysfunction 2 06.06% 
MVPS 2 06.06% 
Valvular Heart Disease 2 06.06% 
Pulmonary Thrombo Embolism 1 03.03% 
Mediastinal Mass 2 06.06% 
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CARDIAC MANIFESTATIONS IN VARIOUS STAGES OF HIV 
STAGE 2 
12.5
87.5
CADIAC DISEASE
OTHERS
 
 No of Patients Percentage 
Cardiac Disease 1 12.5% 
Others 7 87.5% 
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STAGE 3 
18.18%
81.81%
CARDIAC DISEASE
OTHERS
 
 No of Patients Percentage 
Cardiac Disease 14 18.18% 
Others 63 81.81% 
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STAGE 4 
27.69%
72.30%
CARDIAC DISEASE
OTHERS
 
 No of Patients Percentage 
Cardiac Disease 18 27.69% 
Others 47 72.30% 
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COMPARISION BETWEEN VARIOUS STAGES 
0
10
20
30
40
50
60
70
80
90
100
STAGE 2 STAGE 3 STAGE 4
0
75
25
0 0
100
0
16.6
83.3
0
80
20
0
60
40
PULMONARY 
HYPERTENSION
CARDIOMYOPATHY
PERICARDIAL EFFUSION
CAD
Lt VENTRICULAR 
HYPERTROPHY AND DD
 
CARDIAC DISEASE STAGE 3 STAGE 4 
PHT 3 75% 1 25% 
Cardiomyopathy  0 0% 7 100% 
Pericardial Effusion  1 16.6% 5 83.3% 
CAD 4 80% 1 20% 
LVH and DD 3 60% 2 40% 
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INCIDENCE OF CARDIAC DISEASES TO CD4 COUNT 
0
5
10
15
20
25
30
35
15.15
27.27
15.15
33.33
6.06
3.03
<100
101-150
151-200
201-250
250-500
>500
 
 
CD4 COUNT 
NO. OF 
PATIENTS 
PERCENTAGE 
<100 5 15.15% 
101-150 9 27.27% 
151-200 5 15.15% 
201-250 11 33.33% 
251-500 2 06.06% 
>500 1 03.03% 
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PREVALENCE OF SYSTEMIC HYPERTENSION WITH 
CARDIAC DISEASES IN HIV 
24.24
75.76
SHT
NORMOTENSIVES
 
PREVALENCE OF SHT WITHOUT CARDIAC DISEASE IN HIV  
2.56
97.44
SHT
NORMOTENSIVES
 
 No of Patients Percentage 
With Cardiac Disease 8 24.24% 
Without Cardiac Disease 3 2.56% 
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PREVALENCE OF DIABETES WITH CARDIAC DISEASES IN 
HIV 
18.18
91.82
DIABETIC
OTHERS
 
PREVALENCE OF DIABETES WITHOUT CARDIAC DISEASE 
IN HIV  
3.41
96.59
DIABETUS
OTHERS
 
 No of Patients Percentage 
With Cardiac Disease 6 18.18% 
Without Cardiac Disease 4 3.41% 
 
56 
 
INTERESTING ECGS ENCOUNTERED 
ST, rate 120, low voltage, electrical alternans, findings diagnostic of  
pericardial effusion 
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ST S1Q3T3 PATTERN RBBB T WAVE INVERSION IN V1-V3 
SUGGESTIVE OF PULMONARY THROMBOEMBOLISM 
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DISCUSSION 
In this study echocardiographic manifestations of 150 HIV 
patients were analysed irrespective of their CD4 count, stage of disease 
and ART status.     Among them 91.4% are males and 18.6% are 
females.  
They were staged according to WHO clinical staging of 
HIV/AIDS. 5.33% belong to stage 2, 51.33% belong to stage 3 and 
43.33% belong to stage 4. 
The overall incidence of cardiac manifestation is 22% among the 
HIV patients. 
The incidence of cardiac manifestation in males is found to be 
21.6% whereas it is 17.39% in females. Thus the incidence is found to 
be higher in males when compared to females. 
Among the cardiac manifestations the most common is dilated 
cardiomyopathy 21.21% followed by pericardial effusion 18.18%. 
Incidence of other manifestations is coronary artery disease 15.15%, 
pulmonary hypertension 12.12%, left ventricular hypertrophy 9.09%, 
diastolic dysfunction 6.06%, mitral valve prolapse 6.06%, other valvular 
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heart disease 6.06%, pulmonary thromboembolism 3.03% and 
mediastinal mass 6.06%. 
Comparing various stages of HIV, in stage 2 one patient is found 
to have mitral valve prolapse syndrome.  In stage 3 the incidence is 
18.18% and the incidence in stage 4 is 27.69%. This shows that 
incidence of cardiovascular manifestation increases as the disease 
progresses.  
When individual manifestations are compared, incidence of 
dilated cardiomyopathy and pericardial effusion is found to be higher in 
stage 4. The incidence is 100% and 83.3% respectively. Whereas the 
incidence of pulmonary hypertension, coronary artery disease, left 
ventricular hypertrophy and diastolic dysfunction is found to be more in 
stage 3. The incidences are 75%, 80% and 60% respectively. 
Almost 90.9% of manifestations occur when CD4 count is below 
250. 
On analyzing the risk factors for cardiac disease 67.15% of males 
consume alcohol and 64.23% of males smoke. All the females deny 
smoking and alcohol history. 
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Incidence of systemic hypertension is 24.24% in patients with 
cardiac disease and in patients without cardiac disease is 2.56% . 
Incidence of diabetes mellitus is 18.18% in patients with cardiac 
disease and in patients with cardiac disease is 3.41%. This shows that 
the presence of other risk factors like systemic hypertension and 
diabetes increases the incidence of cardiac diseases. 
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CONCLUSION 
¾ Cardiac involvement and cardiovascular complications are 
commonly seen in HIV-infected patients. 
¾ As the epidemic progresses and new treatments help increase the 
long-term survival of affected individuals, cardiovascular 
complications will become more common. 
¾ The common cardiovascular manifestation seen in HIV patients is 
dilated cardiomyopathy.  
¾ The incidence of cardiovascular manifestations increases as the 
disease progresses. 
¾ The presence of risk factors like systemic hypertension and 
diabetes further increases the risk of cardiac diseases. 
¾ Strategies to prevent cardiovascular disease in HIV-infected 
patients should focus on reducing traditional risk factors, as well 
as HIV and ART-specific risk factors. 
¾ Early recognition and prompt treatment are important to prevent 
significant morbidity from cardiac involvement. Whether this 
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approach will prolong survival in AIDS patients remains to be 
seen. 
¾ It’s important to stratify CVD risk in HIV-infected patients. 
Clinicians can use existing general risk stratification algorithms, 
such as the Framingham Risk Score, to measure HIV patients  
risk for heart disease. 
¾ In essence, it means practicing good preventive medicine with all 
patients, including those who have HIV. 
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PROFORMA 
NAME: 
AGE: 
SEX: 
ART NO: 
COMPLAINTS: 
      Sob:  present/absent        duration:         grade: 
      Chest pain:   
      Palpitation: 
      Pedal edema: 
      Abdominal distension: 
      Urine output     adequate /decreased 
 PERSONAL HISTORY: 
     Smoker     yes/no            Alcohol        yes/no 
     DM            yes/no            SHT             yes/no      
CLINICAL FINDINGS: 
      Pallor: 
      Pedal edema: 
      JVP 
      Pulse 
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      BP 
      CVS 
      RS 
INVESTIGATIONS: 
    CD4 COUNT: 
    Bd sugar 
    Urea 
    Creatine 
    LFT 
    CHG 
    ECG 
    ECHO   
DURATION  SINCE DIAGNOSIS 
TREATMENT DETAILS 
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S. 
NO AGE SEX 
STA
GE CD4 
SYMP-
TOM SHT DM 
ALCO
HOL 
SMOK
ING FBS UREA Sr.Cr T.B SGOT SGPT SAP T.PRO 
1 45 M 3 212 N N N Y Y 86 34 1 1 44 42 98 5.2 
2 46 M 4 220 Y N N Y Y 87 32 .8 1.2 48 54 102 6 
3 51 M 4 154 Y N N N Y 96 22 1.1 .8 54 56 86 5.8 
4 56 M 3 112 Y N N N N 110 21 1.2 .8 47 42 88 5.4 
5 38 M 3 112 N N N Y Y 115 16 1.1 1 55 54 104 5.4 
6 56 M 3 143 N N N Y N 87 18 1 1 42 56 112 5.2 
7 43 M 4 134 N N N N Y 94 23 .9 1.2 46 44 96 6.2 
8 46 M 4 120 Y N N Y Y 68 32 .8 1.2 44 62 88 6.4 
9 48 F 4 116 N N N N N 76 43 .9 1.2 48 68 86 6.2 
10 43 M 3 126 Y N N Y Y 89 23 1 1.2 64 48 86 6.6 
11 48 M 4 176 Y N N Y Y 75 22 1. 1.3 48 64 94 5.8 
12 51 M 4 198 N N N Y N 78 23 1.3 1 68 48 98 5.8 
13 47 F 3 154 N N N N N 93 32 1.2 .8 62 44 98 6 
14 43 M 3 145 Y N N Y Y 95 34 1.6 .8 44 46 86 6 
15 57 M 3 144 N N N Y Y 73 22 1 .8 56 42 84 5.5 
16 43 F 3 135 N N N N N 85 21 1.8 1 54 55 82 6 
17 46 M 3 246 N N N Y Y 86 20 1.4 1 42 47 88 6.2 
18 51 M 3 235 Y N N N N 96 24 1 .8 56 54 112 6.2 
19 34 M 3 136 Y N N Y Y 97 26 .8 1.2 54 48 107 6.4 
20 56 F 3 160 N Y N N N 86 22 .8 1.2 42 44 82 5.8 
21 56 F 3 220 N N N N N 86 32 .8 1.2 48 47 88 5.8 
22 34 M 2 302 N N N Y Y 97 33 .8 1.2 64 55 86 6.2 
23 51 M 3 312 N N N N N 96 42 1 .8 48 42 86 6.2 
24 46 M 4 60 N N N Y Y 86 51 1.2 .8 44 46 94 5.8 
25 43 M 4 98 Y N N Y Y 95 22 1.4 1.1 46 44 98 5.6 
26 63 M 3 210 N N N N Y 88 54 .8 1.2 62 68 88 5.5 
27 58 M 4 240 N N N Y Y 85 43 .8 1.2 68 48 118 6 
28 53 M 3 108 N N N N Y 96 25 1 1.4 44 62 86 5.8 
29 62 M 3 110 N N N Y Y 140 18 1.2 .8 68 44 86 5.8 
30 59 M 4 82 N N N Y Y 132 22 1.2 1 48 66 102 5 
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S.NO HB TC 
E
S
R 
PLT ECG FINDINGS ECHO ART 
1 6 2300 32 120000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
2 7 4600 44 88000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
3 6 4400 46 98000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
4 9 3600 56 120000 SR,P PULMONALE,RT AXIS DEVIATION RA RV DILATED,SEVERE PHT N 
5 9 2000 55 140000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
6 8 2200 46 55000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
7 8 4200 33 188000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
8 7 5000 65 36000 ST, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
9 5.4 4400 45 120000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
10 5.5 4600 45 88000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
11 6.4 5200 65 98000 SR ,LOW VOLTAGE COMPLEXES MODERATE PERICARDIAL EFFUSION N 
12 7 5400 32 120000 SR,LOW VOLTAGE COMPLEXES MINIMAL PERICARDIAL AND PLEURAL EFFUSION Y 
13 7.2 4800 34 100000 ST, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
14 9 4600 28 140000 ST, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
15 8.8 4600 33 120000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
16 7.6 4200 45 220000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
17 7 4200 42 120000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
18 8.4 3600 51 130000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
19 8.8 2600 33 98000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
20 8.6 4100 32 96000 SR LVH N STUDY Y 
21 9 4200 45 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
22 6 4200 45 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
23 9 3600 65 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
24 9 2600 32 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
25 8 4100 34 220000 POOR PROGRESSION OF R WAVES GLOBAL HYPOKINESIA DILATED CARDIOMYOPATHY EF 18% Y 
26 5.3 5000 28 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
27 4 4200 34 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
28 7.3 4400 65 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
29 8 8800 32 54000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
30 8.6 6800 54 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
76 
 
  
S.NO 
 AGE SEX STAGE CD4 
SYMP-
TOM SHT DM
ALCO
HOL 
SMO-
KING FBS UREA SrCr T.B SGOT SGPT SAP T.PRO 
31 44 M 4 212 N N N Y Y 86 24 1 1.2 44 46 82 5.6 
32 52 M 3 200 N Y Y Y Y 95 53 .8 1.2 46 42 88 6 
33 42 F 4 156 N N N N N 85 43 .8 1.4 42 55 112 6.2 
34 54 M 3 154 Y N N Y Y 88 32 1.2 .8 55 47 107 6.6 
35 48 M 3 143 N N N N N 96 20 1 1 47 54 82 5.8 
36 56 M 4 132 Y N N Y Y 98 18 1 .8 47 48 98 5.8 
37 32 M 4 123 N N Y N Y 110 19 1.6 .8 46 44 102 6 
38 44 F 2 210 Y N N N N 114 19 1.7 1.2 44 68 118 6 
39 44 M 4 80 N N N Y N 63 18 .8 1.2 48 62 88 5.5 
40 58 M 4 178 N N N Y N 86 20 .8 1.2 64 64 86 5.8 
41 36 M 2 302 N N N Y Y 95 32 .8 1.2 48 42 86 5.8 
42 44 M 4 98 N N N Y Y 85 43 1 1.4 68 60 94 6 
43 49 F 3 102 N N N N N 88 54 1.2 .8 62 62 98 6 
44 50 M 3 117 N N N N N 96 25 1.4 1 44 44 82 5.5 
45 52 F 4 78 N N N N N 98 18 1.2 .8 68 68 88 6 
46 61 M 4 98 N N N Y N 110 22 1.2 .8 48 48 112 6.2 
47 43 M 3 100 N N N Y Y 114 34 1.4 1.2 64 64 107 6.2 
48 52 M 3 212 Y Y N Y Y 63 54 2 1.2 48 48 98 5.4 
49 51 M 4 204 Y N N Y Y 98 56 1.8 .8 54 42 82 5.2 
50 44 M 3 210 N N N Y Y 96 71 2.1 .8 52 52 88 5.2 
51 44 M 3 165 Y N N Y Y 98 18 1.6 1.2 55 47 102 6 
52 52 F 4 168 N N N N N 110 19 1.7 1 47 54 118 5.5 
53 38 F 4 210 N N N N N 114 C .8 1 47 48 88 5.8 
54 46 M 4 214 Y N N Y N 63 18 .8 1.6 46 44 86 5.8 
55 44 M 4 306 N N N Y Y 86 20 .8 1.7 44 68 86 6 
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S.NO HB 28TC ESR PLT ECG FINDINGS ECHO ART 
31 8 3100 32 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
32 8.2 5300 34 80000 NSR Q WAVES IN LEADS 2 3 AND AVF. HYPOKINESIA OF INFERIOR WALL Y 
33 8 6800 28 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
34 7.2 4300 33 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
35 8 2000 28 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
36 8 2200 34 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
37 4 4200 45 50000 NSR LVH NO ST T CHANGES GR 1 DIASTOLIC DYSFUNCTION Y 
38 5.3 5000 65 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
39 9 4400 32 120000 ST POOR PROGRESSION OF R WAVES GLOBAL HYPOKINESIA DCM EF 26% Y 
40 8 6800 34 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
41 8 5500 28 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
42 7 4200 65 140000 NSR NQRS COMPLEX NO ST T CHANGES MEDIASTINAL  LYMPHADENOPATHY Y 
43 7 4200 46 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
44 8 4200 32 220000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
45 8 3600 8 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
46 9 2600 33 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
47 7.2 4100 46 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
48 8 6200 32 80000 NSR LVH NO ST T CHANGES CON LVH Y 
49 8 3100 8 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
50 9 5500 42 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
51 7 6800 34 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
52 7 5500 28 50000 SR ,LOW VOLTAGE COMPLEXES MODERATE PERICARDIAL EFFUSION Y 
53 8 4200 65 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
54 8 4200 46 120000 ST POOR PROGRESSION OF R WAVES NO ST T CHANGES 
GLOBAL HYPOKINESIA DILATED 
CARDIOMYOPATHY EF 20% Y 
55 9 4200 32 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
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S.NO AGE SEX STAGE CD4 SYMP-TOM SHT DM ALCOHOL SMOKING FBS UREA SrCr T.B SGOT SGPT SAP T.PRO 
56 64 M 3 260 N N N Y Y 110 19 1.2 .8 62 62 98 5.5 
57 46 F 4 210 N N N N N 114 19 1.4 .8 44 44 82 6 
58 44 M 4 110 Y N N N N 63 18 1.2 1 44 46 88 6.2 
59 52 F 2 300 N N N N N 86 20 1.2 .8 48 44 88 6 
60 55 M 3 230 Y N Y Y Y 95 32 1.4 1 64 48 112 6.2 
61 44 F 3 210 N N N N N 85 43 2 .8 48 64 107 6.6 
62 47 F 4 31 N N N N N 88 54 1.8 .8 68 48 82 5.8 
63 52 M 3 212 Y N N Y Y 96 25 1.7 1.2 62 68 98 5.8 
64 41 M 3 90 N N N Y Y 96 43 1.6 1 44 62 102 6 
65 38 M 3 100 N N N N N 98 54 1.7 1 68 44 118 6 
66 46 M 3 120 N N N Y Y 110 77 .8 .8 48 64 88 5.5 
67 52 F 3 220 N Y Y N N 114 63 .8 1.2 64 48 86 5.8 
68 43 M 3 250 N N N Y Y 63 19 .8 1.2 48 68 102 6 
69 55 M 4 160 N Y N Y Y 86 19 1 1.2 68 62 118 5.5 
70 43 M 4 200 N N N N N 95 18 1.2 1.2 62 44 88 5.8 
71 47 M 4 80 N N N Y Y 85 20 1.4 1.4 44 44 86 5.8 
72 45 M 3 108 N N N Y Y 88 32 1.2 .8 68 48 86 6 
73 44 M 2 450 N N Y Y Y 96 62 1.2 1 48 64 94 6 
74 39 M 4 108 N N N Y Y 145 34 1.4 2 66 44 98 5.5 
75 40 M 4 100 Y N N Y Y 167 53 1 1.8 54 32 82 6 
76 44 F 3 210 N N N N N 110 77 1.8 .8 64 48 102 6 
77 46 M 4 98 N N N Y Y 114 63 1.7 1.2 48 68 118 6 
78 54 M 3 342 N N N N N 63 19 1.6 1 68 62 88 5.5 
79 57 M 4 210 N N N Y Y 86 19 1.7 1 62 44 86 5.8 
80 60 M 3 246 N Y Y Y Y 95 18 .8 .8 44 44 102 6 
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S.NO HB TC ESR PLT ECG FINDINGS ECHO ART 
56 9 6800 33 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
57 8 4300 46 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
58 8.2 2000 32 140000 SR POOR PROGRESSION OF R WAVE GLOBAL HYPOKINESIA DCM EF 20% N 
59 8 2200 33 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
60 7.2 4200 28 120000 NSR POOR PROGRESSION OF R WAVES HYPOKINESIA OF LV APEX AND IVS EF 40% Y 
61 8 5000 34 140000 NSR RBBB COMPLEX NO ST T CHANGES N STUDY Y 
62 8 4400 45 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
63 4 8800 65 188000 SR ,LOW VOLTAGE COMPLEXES MODERATE PERICARDIAL EFFUSION Y 
64 5.3 4200 32 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
65 7.3 4200 34 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
66 7 3600 28 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
67 7 2600 65 140000 SR LVH WITH STRAIN PATTERN AORTIC SCLEROSIS, CON LVH Y 
68 8 4100 34 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
69 8 6200 28 50000 NSR  LBBB LVH NO ST T CHANGES CON LVH Y 
70 9 3100 65 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
71 7.2 5500 46 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
72 8 6800 32 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
73 8 4300 8 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
74 10 2000 33 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
75 12 2200 46 120000 ST RT AXIS DEVIATION  RBBB P PULMONALE RVH NO ST T CHANGES 
RA RV DILATED PHT SEVERE 
 N 
76 7.3 4200 45 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
77 7 3600 65 188000 NSR NQRS COMPLEX NO ST T CHANGES MEDIASTINAL MASS.?LYMPH NODES N 
78 7 2600 32 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
79 8 4100 34 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
80 8 6200 28 120000 NSR LBBB NO ST T CHANGES GRADE 1 DIASTOLIC DYSFUNCTION Y 
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S.NO AGE SEX STAGE CD4 SYMPTOM SHT DM ALCOHOL SMOKING FBS UREA SrCr T.B SGOT SGPT SAP T.PRO 
81 44 M 3 122 N N N Y Y 85 54 .8 1.2 66 44 88 5.5 
82 46 F 3 240 N N N N N 86 25 .8 1.2 54 44 88 5.8 
83 56 M 4 220 Y N N Y N 95 20 1 1.8 62 48 112 6 
84 53 M 3 168 Y Y N N N 85 32 1.2 1.7 44 64 107 5.5 
85 43 M 3 190 N N N N N 102 43 .8 1.6 46 48 82 5.8 
86 42 M 4 200 N N N Y Y 132 54 1.2 1.7 44 68 98 5.8 
87 32 M 4 100 N N N Y Y 99 25 1 .8 48 62 88 6.2 
88 54 M 4 98 N N N Y Y 86 43 1 .8 64 46 82 6 
89 52 M 4 110 Y N N Y N 60 18 .8 .8 66 44 98 6 
90 36 M 3 122 Y N N N Y 110 20 .8 1 54 48 88 5.5 
91 43 M 3 110 N N N Y Y 85 25 1.2 1.7 44 44 88 6.2 
92 44 M 3 212 N N N Y Y 88 20 1 1.6 46 44 88 6.6 
93 45 M 3 241 N N N Y Y 78 32 1 1 48 62 98 6.2 
94 61 M 3 216 Y Y Y Y Y 108 85 44 1 64 44 82 6 
95 34 M 4 30 N N N Y Y 109 86 43 1.2 66 46 88 6.2 
96 54 M 4 120 N N N Y Y 99 51 .8 .8 54 44 88 6.6 
97 43 M 3 110 N N N N N 110 45 .8 1.2 48 48 112 5.8 
98 36 M 4 154 N N N Y Y 121 34 .8 1.2 64 64 107 5.8 
99 32 M 3 208 N N N Y Y 132 24 1 1.2 48 44 82 6 
100 45 M 3 186 N N N Y Y 154 32 1.2 1.2 68 42 76 5 
101 44 M 3 110 N N N Y Y 89 32 .8 .8 64 47 102 6.2 
102 46 M 4 123 N N N N N 75 43 .9 1 48 55 86 6.6 
103 51 F 4 324 N N N N N 78 23 1 1 44 42 88 5.8 
104 50 F 3 108 Y N N N N 93 22 1. 1.2 46 46 104 5.8 
105 48 M 3 210 N N N Y Y 95 23 1.3 1.2 42 44 112 6 
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S.NO HB TC ESR PLT ECG FINDINGS ECHO ART 
81 8 2000 46 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
82 8 2200 33 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
83 9 4200 46 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
84 7.2 5000 32 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
85 8 2200 33 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
86 9 4200 28 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
87 8 5000 34 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
88 8.2 2200 45 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
89 8 4200 65 140000 NSR NQRS COMPLEX NO ST T CHANGES MILD PERICARDIAL EFFUSION N 
90 7.2 6600 22 100000 NSR LAE N QRS COMPLEX NO ST T CHANGES RHEUMATIC MS MVO 1.2 CM 
2 MODERATE 
PHT Y 
91 8.2 2000 8 78000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
92 8 2200 22 100000 NSR RBBB NO ST T CHANGES N STUDY Y 
93 7 4200 45 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
94 7 3600 65 76000 ST N QRS COMPLEX QS COMPLEX IN V1-V4 HYPOKINESIA OF ENTIRE ANTERIOR WALL EF 34% Y 
95 8 2600 32 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
96 8 4100 34 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
97 9 6200 28 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
98 7.2 3100 65 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
99 8 5500 34 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
100 9 6800 28 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
101 5.4 5000 46 140000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
102 5.5 4400 56 55000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
103 6.4 4600 55 188000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
104 7 5200 46 36000 ST, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
105 7.2 5400 33 120000 
NSR NQRS COMPLEX OCC PREMATURE 
VENTRICULAR COMPLEX POOR PROGRESSION OF 
R WAVES NO ST T CHANGES 
HYPOKINESIA OF ANTERIOR WALL EF 18% Y 
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S.NO AGE SEX STAGE CD4 SYMPTOM SHT DM ALCOHOL SMOKING FBS UREA SrCr T.B SGOT SGPT SAP T.PRO 
106 43 F 2 260 N N N N N 88 53 1.2 1.2 55 64 88 6.2 
107 57 M 4 110 N N N Y Y 85 24 1.2 .9 42 48 82 6 
108 47 M 3 280 N N N N N 96 43 1.4 1 47 48 112 6.6 
109 51 M 3 310 N N N Y Y 98 32 .8 1 54 68 107 5.8 
110 48 M 4 210 Y N N Y Y 110 20 1 1 48 62 82 5.8 
111 46 M 3 100 Y N N N N 114 18 .8 1.2 44 44 98 6 
112 43 F 3 145 Y N N N N 63 19 .8 1.2 68 68 102 6 
113 56 M 4 243 Y N N Y Y 76 22 1.2 1 62 48 118 5.5 
114 38 M 4 220 N N N N N 75 22 1.2 .8 44 64 94 6 
115 56 M 3 240 Y N N Y Y 83 42 1 .8 56 48 96 6.2 
116 51 M 4 110 N N Y Y Y 92 34 1.2 1.2 54 44 96 6.2 
117 46 M 4 62 N N N Y Y 100 21 1 1.2 42 46 96 5.4 
118 45 M 3 110 N N N N Y 73 18 .8 1.1 56 42 88 5.2 
119 48 M 3 240 N N N Y N 84 18 .8 1.2 54 55 86 6.2 
120 53 M 3 322 N Y N Y Y 86 20 .8 .8 42 47 102 6.4 
121 43 M 3 220 N N N Y Y 95 32 1 .8 48 62 94 6 
122 50 M 3 168 N N N Y Y 85 43 1.2 .8 64 64 98 5.5 
123 49 F 3 779 Y N N N N 88 54 1.4 .8 48 42 82 6 
124 34 M 2 340 N N N Y Y 96 77 1.2 1 68 60 88 6.2 
125 35 M 4 150 N N N Y Y 98 63 1.2 .8 62 62 88 6 
126 56 M 3 120 N N Y Y Y 110 19 1.4 1 44 44 112 6.2 
127 53 M 4 110 Y N N Y Y 114 19 2 .8 44 46 107 6.6 
128 42 M 3 144 N N N Y Y 63 18 1.8 .8 48 44 82 5.8 
129 46 M 3 168 N N N N N 86 20 1.7 1.2 64 48 98 5.8 
130 56 M 3 220 N N N N N 95 32 .8 1.2 48 64 102 6 
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S.NO HB TC ESR PLT ECG FINDINGS ECHO ART 
106 7 3100 33 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
107 8 6200 28 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
108 7 5500 28 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
109 8 6800 34 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
110 8 4300 32 120000 POOR PROGRESSION OF R WAVES GLOBAL HYPOKINESIA DILATED CARDIOMYOPATHY EF 26% Y 
111 9 2000 66 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
112 7.4 2200 65 55000 NSR RVH RT AXIS DEVIATION RA RV DILATED SEVERE PHT Y 
113 9.2 4200 46 188000 NSR LVH NO ST T CHANGES ANTERIOR MITRAL LEAFLET PROLAPSE Y 
114 5.6 5000 32 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
115 8 4400 8 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
116 8.2 4600 33 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
117 8 5200 32 88000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
118 7.2 5400 44 86000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
119 8 4800 42 90000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
120 8 3300 42 100000 NSR LVH NO ST T CHANGES CON LVH Y 
121 7.2 3600 8 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
122 8 2600 33 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
123 8 4100 46 120000 ST S1 Q3 T3 PATTERN RAE RBBB NO ST T CHANGE RA RV DILATED WITH THROMBUS IN MAIN PULMONARY TRUNK Y 
124 9 6200 32 140000 NSR NQRS COMPLEXES NO ST T CNANGES ANT MITRAL LEAFLET PROLAPSE N 
125 8 3100 33 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
126 8.2 5500 28 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
127 8 6800 34 140000 ST POOR PROGRESSION OF R WAVE GLOBAL HYPOKINESIA DCM EF 34% Y 
128 7.2 4300 45 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
129 8 2000 65 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
130 8 2200 32 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
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S.NO AGE SEX STAGE CD4 SYMPTOM SHT DM ALCOHOL SMOKING FBS UREA SrCr T.B SGOT SGPT SAP T.PRO 
131 36 F 2 340 N N N N N 86 32 .8 1.2 68 48 118 5.5 
132 45 F 4 100 N N N N N 95 43 .8 1.2 48 64 88 5.8 
133 46 M 4 118 Y N N N N 85 44 1 1.2 66 44 86 5.8 
134 53 M 3 98 N Y Y Y Y 86 43 1.2 1.2 54 32 98 6.2 
135 50 M 4 53 N N Y Y Y 95 54 .8 1.8 62 62 82 6 
136 44 M 4 114 N N Y Y Y 85 25 1.2 1.7 44 44 88 6.2 
137 41 M 4 88 Y N Y Y Y 88 20 1 1.6 46 44 88 6.6 
138 37 M 3 198 N N N Y Y 96 32 1 1.7 44 48 112 5.8 
139 48 M 3 186 N N N N N 96 43 .8 .8 48 64 107 5.8 
140 46 F 3 144 N N N N N 98 54 1.2 .8 64 48 82 6 
141 37 M 4 166 N N N Y Y 110 25 1.2 .8 66 68 98 6 
142 39 F 3 158 N N N N N 114 43 1.2 1 54 62 88 5.5 
143 44 M 4 36 N N N Y Y 63 54 1.8 1.2 62 44 86 6.2 
144 43 M 3 206 Y N N N N 126 77 1.7 1.4 44 68 98 6.4 
145 52 M 4 224 N N N Y Y 144 42 1.6 1 44 82 82 6 
146 46 F 3 222 N N N N N 73 16 1.2 1.2 55 48 96 6 
147 50 M 3 210 Y Y N N Y 85 18 1.6 1.2 47 64 88 5.5 
148 38 M 3 176 N N N Y Y 86 23 1 1.3 54 48 102 6 
149 44 M 4 268 N N Y N N 96 32 1.8 1 48 68 86 6.2 
150 45 M 4 78 N N N Y Y 97 43 1.4 .8 44 62 88 6.2 
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S.NO HB TC ESR PLT ECG FINDINGS ECHO ART 
131 9 3100 65 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
132 7.2 5500 34 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY N 
133 8 6800 28 50000 SR ,LOW VOLTAGE COMPLEXES MODERATE PERICARDIAL EFFUSION Y 
134 9 6800 65 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
135 8 4300 46 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
136 8.2 2000 33 80000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
137 8 2200 46 120000 AF N QRS COMPLEX POOR PROGRESSION OF R WAVE 
GLOBAL HYPOKINESIA DILATED 
CARDIOMYOPATHY EF 32% Y 
138 7.2 4200 32 140000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
139 8 5000 33 55000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
140 8 2200 28 188000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
141 4 4200 34 50000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
142 5.3 5000 45 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
143 10 4400 65 120000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
144 12 8800 22 140000 ST RT AXIS DEVIATION  RBBB P PULMONALE RVH NO ST T CHANGES 
RA RV DILATED PHT MODERATE 
 Y 
145 7.8 4200 65 100000 NSR NQRS COMPLEX NO ST T CHANGES N STUDY Y 
146
  9 4800 65 88000 
SR, N QRS COMPLEXES NO ST T 
CHANGES N STUDY N 
147 8.8 4600 45 98000 NSR N QRS COMPLEX LVH NO ST T CHANGES AORTIC SCLEROSIS Y 
148 7 4600 45 120000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
149 7.2 4200 65 100000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY N 
150 9 4200 32 140000 SR, N QRS COMPLEXES NO ST T CHANGES N STUDY Y 
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ABBREVIATIONS 
HIV    -  Human Immunodeficiency Virus 
ART  -  Anti Retroviral Therapy 
PI        -  Protease Inhibitors 
SHT    -  Systemic Hypertension 
DM     -  Diabetes mellitus 
AHA   -  American Heart Association 
DCM   - Dilated cardiomyopathy 
EF       - Ejection Fraction 
PHT    - Pulmonary Hypertension 
PE      - Pericardial Effusion 
RA     - Right atrium 
RV     - Right ventricle 
LA      - Left atrium 
LV      - Left ventricle 
IVS     -  Interventricular septum 
MS     - Mitral stenosis 
DD      - Diastolic Dysfunction 
NCEP - National Cholesterol Eradication Program 
FBS     - Fasting Blood Sugar 
RFT     - Renal function test 
LFT    - Liver function test 
CHG   - Complete haemogram 
AACTG   - Adults AIDS Clinical Trial Group  
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